Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Otte

Showing results (291-300 of 310) with videos related to

Pageof 31
Sort By:
Epilepsia|May 20, 2025
Comparison of children and adults undergoing subdural grid electrode implantation or stereoelectroencephalography in a refractory epilepsy cohort from four European centersMatea Rados, Shanice Beerepoot, Martin M Tisdall, et al.
Restorative Neurology and Neuroscience|January 7, 2017
Recent progress in translational research on neurovascular and neurodegenerative disordersHans-Ulrich Demuth, Rick M Dijkhuizen, Tracy D Farr, et al.
Journal of Medicinal Chemistry|April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"Elsie C Yu, Hua Zhou, Xin Yan, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery of Potent 1,3-Cyclobutane-Containing Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonists with Low Projected Human Dose for the Treatment of CancerZachary G Brill, Alec H Christian, Lorena Rico, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
The Review of Scientific Instruments|November 29, 2014
Status of the diagnostics development for the first operation phase of the stellarator Wendelstein 7-XR König, W Biel, C Biedermann, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2010
Purine derivatives as potent gamma-secretase modulatorsAlexey Rivkin, Sean P Ahearn, Stephanie M Chichetti, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Pageof 31

Showing results (291-300 of 310) with videos related to

Sort By:
Pageof 31
Epilepsia|May 20, 2025
Comparison of children and adults undergoing subdural grid electrode implantation or stereoelectroencephalography in a refractory epilepsy cohort from four European centersMatea Rados, Shanice Beerepoot, Martin M Tisdall, et al.
Restorative Neurology and Neuroscience|January 7, 2017
Recent progress in translational research on neurovascular and neurodegenerative disordersHans-Ulrich Demuth, Rick M Dijkhuizen, Tracy D Farr, et al.
Journal of Medicinal Chemistry|April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"Elsie C Yu, Hua Zhou, Xin Yan, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery of Potent 1,3-Cyclobutane-Containing Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonists with Low Projected Human Dose for the Treatment of CancerZachary G Brill, Alec H Christian, Lorena Rico, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
The Review of Scientific Instruments|November 29, 2014
Status of the diagnostics development for the first operation phase of the stellarator Wendelstein 7-XR König, W Biel, C Biedermann, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2010
Purine derivatives as potent gamma-secretase modulatorsAlexey Rivkin, Sean P Ahearn, Stephanie M Chichetti, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Pageof 31